



# Innovations in Vitreous Macula Retina

Presented by:

**J. Sebag**

**MD, FACS, FRCOphth, FARVO  
VMR Institute  
for Vitreous Macula Retina**

When:

**Tuesday, OCTOBER 27<sup>th</sup>, 2015**

**4:00 – 5:00 p.m.**

Where:

**Research Conference Center  
734 Fairmount Avenue  
Pasadena, CA 91105**

**ABOUT THE SPEAKER:**

Educated at the Bronx High School of Science, Columbia and Harvard, Dr. Sebag is considered one of the world's leading authorities on vitreous. He has authored 3 books, 69 peer-reviewed articles, 49 chapters, and 55 letters, editorials, and reviews on diseases, drug injection therapy, laser treatments and surgery of the vitreous, macula and retina (VMR). Currently a full Professor of Clinical Ophthalmology at the Doheny Eye Institute, Dr. Sebag has been visiting professor at many institutions throughout the world. A fellow of the American College of Surgeons and the Royal College of Ophthalmologists (UK), Dr. Sebag has received many awards. In 2006 he was inducted as a member of the prestigious American Ophthalmological Society. In 2010 he was designated as a fellow of ARVO, the world's premier eye research organization. Dr. Sebag is Editor-in-Chief of a multi-author text on vitreous published by Springer in November 2014.

**ABOUT THE TALK:**

This lecture will review the biochemistry, anatomy, and physiology of the vitreous body, with emphasis on the vitreo-retinal interface. Proteomic studies of *in utero* human vitreous development will be presented that may provide insights into the underlying mechanisms of blood vessel regression, perhaps opening new avenues of R & D to control pathologic ocular neovascularization and systemic metastatic carcinoma. The pathophysiologic mechanisms resulting in various diseases such as rhegmatogenous retinal detachment and macular holes will be reviewed, standard of care therapies will be described and demonstrated with video recordings, and new forms of non-surgical pharmacologic vitreolysis therapy will be presented.

**TARGET AUDIENCE:** Researchers, clinicians and students of medicine and science.

**LEARNING OBJECTIVES:**

1. Understand how developmental and aging changes in vitreous impact the macula and retina to cause vision loss.
2. Recognize when vitreo-retinal pathologies are potential causes of vision loss and refer patients accordingly.
3. Appreciate the surgical therapies available today and refer patients to surgeons able to treat these conditions.
4. Understand the ways that pharmacotherapies are beginning to replace surgical interventions.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Institute for Medical Quality/California Medical Association (IMQ/CMA) through the joint providership of Huntington Hospital and Huntington Medical Research Institutes. The Huntington Hospital is accredited by the IMQ/CMA to provide continuing medical education for physicians."

Huntington Hospital designates this live activity for a maximum of **1 hour** of **AMA PRA Category 1 Credit™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



**HMRI**  
Huntington Medical Research Institutes



**Huntington Hospital**